Stock Analiz

Artivion, Inc. AORT

Medical/Dental Instruments · data as of November 13, 2026

$19.10Market cap $932M
Open the interactive analysis →

Artivion, Inc. (AORT) is a healthcare company listed in the US with a market value of about $932M. In the twelve months to September 30, 2026 it had revenue of $482M and net income of -$18M, a net margin of -3.7%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

About Artivion

Artivion is listed in the US and classified in medical/dental instruments. Revenue went from $145M in 2014 to $441M in 2025, growth of about 10.7% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E44.6
P/FCF—
P/S1.9
P/B2.1
EV/EBITDA34.6
PEG—
Dividend yield0.00%
FCF yield-4.8%
Shareholder yield0.0%
Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)13.6%
Revenue growth (5 yrs, per year)11.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4.2%
ROIC (5-yr avg.)2.1%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$482M$441M$389M$354M$314M$299M$253M$276M$263M$190M$180M
Net income-$18M$10M-$13M-$31M-$19M-$15M-$17M$2M-$3M$4M$11M
Free cash flow-$44M$839000$11M$9M-$16M-$16M$5M$8M$4M$4M$14M
EPS (diluted)$-0.36$0.21$-0.32$-0.75$-0.48$-0.38$-0.44$0.05$-0.08$0.11$0.32
Net margin-3.7%2.2%-3.4%-8.7%-6.1%-5.0%-6.6%0.6%-1.1%1.9%6.0%
ROIC—3.2%4.8%0.7%0.8%1.0%0.4%2.6%1.5%1.3%4.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $38.47, 101% above the current price; targets range from $30.00 to $45.00; the consensus rating is “Strong buy”; expected EPS is $0.37 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Artivion stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Artivion pay a dividend?

Not currently.

Is Artivion a good stock to buy?

We do not give buy or sell advice. Artivion scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.